Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Cost of Revenue: 2023-2025

Historic Cost of Revenue for Fennec Pharmaceuticals (FENC) over the last 3 years, with Sep 2025 value amounting to $5.2 million.

  • Fennec Pharmaceuticals' Cost of Revenue rose 13.24% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 10.33%. This contributed to the annual value of $18.4 million for FY2024, which is 51.99% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Cost of Revenue of $5.2 million as of Q3 2025, which was up 19.66% from $4.4 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Cost of Revenue peaked at $5.2 million during Q3 2025, and registered a low of $2.3 million during Q2 2023.
  • Its 3-year average for Cost of Revenue is $3.9 million, with a median of $3.9 million in 2024.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Cost of Revenue surged by 105.81% in 2024, and later plummeted by 43.42% in 2025.
  • Over the past 3 years, Fennec Pharmaceuticals' Cost of Revenue (Quarterly) stood at $3.9 million in 2023, then increased by 1.96% to $3.9 million in 2024, then rose by 13.24% to $5.2 million in 2025.
  • Its Cost of Revenue was $5.2 million in Q3 2025, compared to $4.4 million in Q2 2025 and $2.9 million in Q1 2025.